

The 4-Year Course of Tic Disorders in Boys With Attention-Deficit/Hyperactivity Disorder

Thomas Spencer, MD; Joseph Biederman, MD; Barbara Coffey, MD; Daniel Geller, MD; Timothy Wilens, MD; Stephen Faraone, PhD

Background: Despite long-standing clinical concerns, relatively little is known about the comorbidity between attention-deficit/hyperactivity disorder (ADHD) and tic disorders. Therefore, we examined tic disorders in an ongoing prospective follow-up study of male subjects with ADHD, a sample unselected for any comorbid disorder.

Methods: One hundred twenty-eight male children and adolescents with ADHD and 110 male controls were comprehensively evaluated at baseline and 4 years later. We characterized tic disorders along with a wide range of neuropsychiatric correlates, including other comorbid disorders and indices of psychosocial function in multiple domains (school, cognitive, social, and family).

Results: Compared with controls, subjects with ADHD showed more tic disorders at baseline and more new on-

sets were reported at follow-up. Attention-deficit/hyperactivity disorder and tic disorders appeared to be independent in course: in contrast to low rates of ADHD remission, tic disorders mostly remitted. The age-adjusted rate of ADHD remission was 20% and that of tic remission, 65%. Tic disorders had little effect on the psychosocial functioning of subjects with ADHD.

Conclusions: These findings suggest that comorbidity with a tic disorder has a limited effect on ADHD outcome. However, because of the relatively small sample of subjects with tic disorders, our conclusions should be considered preliminary until confirmed in larger studies of medicated and unmedicated children with ADHD with and without tic disorders.

Arch Gen Psychiatry. 1999;56:842-847

FOLLOW-UP STUDIES of children with attention-deficit/hyperactivity disorder (ADHD) have not assessed tic disorders; therefore, the effect of this comorbidity on ADHD outcome is unknown. Moreover, the few cross-sectional studies that examined this issue have reported contradictory findings. For example, 2 studies indicated that the severity of the tic disorder was associated with higher ratings of depression and aggression in children with ADHD,^{1,2} while other studies reported limited consequences of this comorbidity in youth with ADHD.³⁻⁵

Although stimulants had been thought to precipitate tic symptoms in children with ADHD, the extant literature on the subject is equivocal. Two retrospective surveys provide mixed but relatively low estimates of risk (0.9%⁶ and 9%⁷) for the de novo development of tic disorders in children with ADHD. In contrast, 3 controlled, acute treatment studies report higher rates of de novo development of tics in children with ADHD (stimulant vs placebo: 15% vs 15%,⁸ 28% vs 18%,⁹ and 60% vs 0%¹⁰). However, in these 5 reports there were few cases (2 [0.1%] of

1860 subjects)^{6,7} in whom tics did not diminish after stopping medication.

The literature on stimulant exacerbation of preexisting tics in children with ADHD is similarly mixed. Uncontrolled investigations report stimulant-associated tic exacerbation in 78 (31%) of 253 subjects (9 studies) with Tourette syndrome (TS) (range, 0%-100%)¹¹⁻¹⁹ and in 6 (13%) of 45 subjects (1 study) with tic disorder.⁶ Recent short-term controlled studies of TS have reported rates of tic exacerbation ranging from 0%^{20,21} to 15%²² and up to 36%.²³ In an open prospective longitudinal study,²² 15% of children with ADHD with TS discontinued stimulants due to a perceived deleterious effect on tics. In a 2-year follow-up of stimulant-treated children with ADHD and TS,²⁴ tics generally improved and there were no adverse effects from stimulants.

Whether comorbid tics affect the course of ADHD and whether treatment for ADHD affects the course of tics has important clinical implications. The risk vs benefit analysis of the safety of stimulant treatment in children with ADHD with comorbid tics hinges on resolving unanswered questions: Does stimulant treatment precipitate tic disorders or worsen

From the Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, and the Department of Psychiatry, Harvard Medical School, Boston; the Harvard Institute of Psychiatric Epidemiology and Genetics, Harvard Medical School (Dr Faraone), Boston, Mass; and the Tourette's Syndrome Clinic (Dr Coffey), McLean Hospital (Dr Geller), Belmont, Mass.

SUBJECTS AND METHODS

Methods^{25,26} and an overview of results²⁵ have been extensively described in previous reports.

SUBJECTS

The sample consisted of 238 male subjects representing 91.4% of the subjects with ADHD and 91.6% of the normal controls seen at baseline.²⁵ Seventy (54%) of 128 subjects with ADHD were ascertained from referrals to a pediatric psychiatric clinic and 58 (45%) of 128 were ascertained from referrals to a pediatric clinic.²⁶ Eligible subjects were white, non-Hispanic males aged 6 to 17 years with IQs greater than 80. We excluded adopted children and stepchildren, and children with low socioeconomic status, major sensorimotor handicaps, mental retardation, psychosis, or autism. Three hundred ninety-two probands with ADHD were referred. Of these, 252 (64%) were excluded because (1) they did not meet research criteria for ADHD on structured interview, (2) they met exclusion criteria, or (3) they refused participation.²⁶

ASSESSMENTS

Assessments at baseline and 4-year follow-up employed identical methods. Follow-up assessments were made for the interval period and were made blind to prior assessments. All psychiatric assessments relied on the Kiddie Schedule for Affective Disorders and Schizophrenia, Epidemiological version (*DSM-III-R*)²⁷ and were based on interviews with the mothers and direct interviews of offspring aged 12 years or older. Based on 173 interviews, the median κ coefficient of agreement between raters and senior clinicians was 0.86. For the diagnoses of tics and TS, perfect reliability was established ($\kappa = 1.0$).

We estimated IQ from subtests of the Wechsler Intelligence Scales–Revised²⁸ and academic achievement from the Wide Range Achievement Test.²⁹ The definition of learning disabilities under Public Law 94-142 requires a significant discrepancy between a child's aptitude and achievement.³⁰ As recommended by Reynolds,³¹ we first converted the estimated Full-Scale IQ and achievement scores to z

scores, ZIQ and ZA. We then estimated the expected achievement scores, ZEA, by the regression equation $ZEA = r_{IQA} \times ZIQ$, where r_{IQA} is the correlation between IQ and achievement. The discrepancy score is $ZEA - ZA$ and its standard deviation is

$$\sqrt{1 - r_{IQA}^2}$$

We defined as LD any subject who had a value greater than 1.65 on the standardized discrepancy score:

$$\frac{ZEA - ZA}{\sqrt{1 - r_{IQA}^2}}$$

To evaluate school functioning, we assessed placement in special classes, in-school tutoring, and repeated grades. Psychosocial functioning was assessed with the Global Assessment of Functioning scale of the *DSM-III-R* (1 = worse, 90 = best).³² Socioeconomic status was measured using the 4-factor Hollingshead scale (1 = highest, 4 = lowest).³³ The social competency scales of the Child Behavior Check List³⁴ (*t* score) (mean, 50; SD, 10; higher values are better) measured adaptive functioning in activities, social functioning, and school functioning. The Social Adjustment Inventory for Children and Adolescents (12, best; 48, worst) was used to examine interpersonal functioning.^{35,36} Measures of family functioning were obtained using the Moos Family Environment Scale³⁷ along 3 dimensions: cohesion (1, worst; 68, best), expressiveness (15, worst; 73, best), and conflict (32, best; 81, worst).

STATISTICAL ANALYSES

Categorical data were analyzed by χ^2 analysis. Parametric testing of continuous data were analyzed by 1-way analysis of variance, nonparametric data by the Wilcoxon rank sum test. Continuous and binary dependent variables were analyzed using regular and logistic regressions when correcting for age differences. The Kaplan-Meier method was used for survival analysis to estimate lifetime prevalence rates and to generate survival curves, which were compared with the Cox proportional hazards model. The software used for analyses was STATA: Release 5.³⁸ To protect against type II errors, we set a low threshold for statistical significance of 5%. All statistical tests were 2 tailed.

preexisting tics? Similarly, if tic disorders adversely affect ADHD outcome, that would underscore the clinical importance of detecting and treating tic disorders in children with ADHD.

This study uses data from our large, prospectively followed sample of male children and adolescents with ADHD to systematically evaluate the effect of tic disorders on the course and outcome of ADHD. We addressed the following primary research questions: (1) Are tic disorders overrepresented in male children and adolescents with ADHD? (2) Do the natural histories of tic disorders and ADHD diverge by mid adolescence? (3) Do tic disorders affect the outcome of ADHD in a 4 year follow-up period? We also used this data to perform an exploratory analysis: Do stimulants adversely affect the outcome of tic disorders in a 4-year follow-up period?

RESULTS

The overall rate of tic disorders was significantly greater in the children with ADHD vs controls (43/128 [34%] vs 7/110 [6%], $\chi^2_1 = 26$, $P < .001$). The rate of tic disorders in subjects with ADHD did not differ by referral source (26/70 [37%] vs 17/58 [29%], $\chi^2_1 = 0.9$, $P = .35$; psychiatric vs pediatric ascertainment, respectively). Among children who did not have a tic disorder reported at baseline, those with ADHD had a greater probability of having a tic disorder reported only at follow-up (21/106 [20%] vs 3/106 [3%], $\chi^2_1 = 15$, $P < .001$). In addition, the probability of a tic disorder being reported only at follow-up was greatest in the ADHD group that was youngest at baseline (12/36 [33%] aged 6-8 years, 5/38 [13%] aged 9-12 years, 4/32 [13%] aged 13 years

Characteristics of Sample and Functional Outcome*†

Characteristics of Sample	Mean ± SD or No. (%)				Test	P
	ADHD + Tics Baseline (n = 22)	ADHD + Tics Follow-up (n = 21)	ADHD (n = 85)	Controls (n = 110)		
Baseline age of probands, y	10.0 ± 2.5	9.3 ± 3.3	11.0 ± 3.0	11.6 ± 3.6	F _{2,125} = 3.04	.05
Socioeconomic status	2.2 ± 1.0	1.5 ± 0.9	1.8 ± 1.0	1.5 ± 0.7	F _{2,125} = 2.2	.12
Intact families	14 (64)	17 (81)	62 (73)	90 (82)	χ ² ₂ = 1.6	.44
Total No. of DSM-III-R ADHD symptoms	11.0 ± 2.3	12.1 ± 2.0	11.4 ± 1.9	1.7 ± 1.9	F _{2,125} = 1.94	.15
Inattentive	5.0 ± 1.1	5.3 ± 0.9	5.3 ± 0.9	0.9 ± 1.3	F _{2,125} = 0.58	.56
Hyperactive/impulsive	6.0 ± 1.7	6.8 ± 1.5	6.1 ± 1.5	0.8 ± 1.1	F _{2,125} = 2.03	.14
Age at onset of ADHD, y	3.0 ± 2.0	2.3 ± 1.6	2.7 ± 2.2	NA	F _{2,125} = 0.59	.56
Duration of ADHD, y	10.6 ± 3.0	10.5 ± 3.9	11.6 ± 3.9	NA	F _{2,125} = 1.2	.32
Impairment of ADHD	2.7 ± 0.5	2.9 ± 0.4	2.6 ± 0.5	NA	F _{2,125} = 1.59	.21
Additional comorbid disorders						
Conduct	6 (27)	7 (33)	23 (27)	6 (5)	χ ² ₂ = 0.34	.85
Oppositional-defiant	15 (68)	17 (81)	61 (72)	18 (16)	χ ² ₂ = 0.98	.61
Depression	11 (50)	10 (48)	37 (44)	7 (6)	χ ² ₂ = 0.35	.84
Bipolar	4 (18)	5 (24)	6 (7)	0 (0)	χ ² ₂ = 5.6	.06
Multiple anxiety, ≥2	9 (41)	8 (38)	28 (33)	10 (9)	χ ² ₂ = 0.58	.75
Obsessive-compulsive	4 (18)	3 (14)	7 (8)	1 (1)	χ ² ₂ = 2.06	.36
Functional outcome						
Cognitive functioning						
Full IQ	106 ± 16	107 ± 14	111 ± 13	119 ± 10	F _{2,124} = 0.17	.19
Learning disorders, %‡	8 (38)	5 (26)	25 (31)	12 (11)	χ ² ₂ = 0.68	.71
School functioning						
Repeated grade	8 (36)	6 (29)	26 (31)	12 (11)	χ ² ₂ = 0.36	.84
Extra help	12 (55)	11 (52)	49 (58)	28 (25)	χ ² ₂ = 0.22	.90
Special class	9 (41)	8 (38)	24 (28)	1 (1)	χ ² ₂ = 1.7	.42
Psychosocial functioning						
Past GAF	51.9 ± 7.7	49.9 ± 7.8	54.3 ± 7.8	67 ± 7.7	F _{2,125} = 2.99	.05
Current GAF	55.4 ± 7.6	53.0 ± 6.8	57.2 ± 7.4	69 ± 6.0	F _{2,125} = 2.83	.06
Interpersonal (SAICA)	20 ± 11	19 ± 10	18 ± 12	12 ± 10	F _{2,125} = 0.17	.85
Child Behavior Checklist (social)	52.8 ± 23	51.3 ± 23	57.6 ± 25	57 ± 14	F _{2,103} = 0.64	.53
Moos FES						
Cohesion	53 ± 17	52 ± 19	47 ± 19	58 ± 14	F _{2,107} = 0.84	.43
Expressive	55 ± 12	57 ± 12	50 ± 15	54 ± 13	F _{2,107} = 1.95	.15
Conflict	52 ± 11	55 ± 9	56 ± 12	48 ± 12	F _{2,107} = 1.06	.35

*ADHD indicates attention-deficit/hyperactivity disorder; NA, not applicable; GAF, Global Assessment of Functioning scale; SAICA, Social Adjustment Inventory for Children and Adolescents; and FES, family environment scale.

†Analyses were performed among ADHD subgroups only (ADHD + tic disorder baseline, ADHD + tic disorder follow-up, and ADHD without tic disorder).

‡Categorical data were analyzed by χ² analysis. Continuous data were analyzed by 1-way analysis of variance.

§Not all subjects were assessed for learning disorders. The denominators were ADHD + tic disorder baseline, n = 21; ADHD + tic disorder follow-up, n = 19; ADHD, n = 81; and controls, n = 106.

or older; χ²₂ = 6.3, P < .05). The number of cases of tic disorders with TS was 12 (55%) of 22 at baseline and 6 (29%) of 21 at follow-up. Statistical comparisons were made between 3 groups of ADHD patients: (1) those who had a tic disorder reported at baseline (ADHD and tic disorder at baseline; n = 22), (2) those whose tic disorder was reported only at follow-up (ADHD and tic disorder at follow-up; n = 21), and (3) those without a report of tic disorder at baseline or follow-up (ADHD; n = 85). Other than for comparisons of rates of tic disorders, findings in controls without ADHD (n = 110) are presented for reference only.

CLINICAL CHARACTERISTICS OF ADHD AND TIC DISORDERS

There were no significant differences between the 3 ADHD groups in age, percentage of intact families, or socioeconomic status. Subjects with ADHD with and without tic disorders had a similar mean number of ADHD symptoms, age at onset, and duration of ADHD. On average,

ADHD impairment was rated between moderate to severe (mean, 2.7; mild = 1, moderate = 2, severe = 3) in all groups (**Table**).

The onset of tic disorders was overwhelmingly prepubertal in both ADHD groups with comorbid tic disorders (onset of tic disorder at age ≤ 12 years: 21 (95%) of 22 vs 18 (86%) of 21, χ²₁ = 1.1, P > .10; mean age of onset: 6.1 ± 3.0 vs 8.0 ± 4.6 years, F_{1,40} = 2.4, P > 0.1, in ADHD and tic disorder at baseline and ADHD and tic disorder at follow-up, respectively). Nine (43%) of 21 of the subjects with ADHD and tic disorder at follow-up reported that the onset of the tic disorder was earlier than their age at baseline. Most ADHD cases with comorbid tics satisfied criteria for chronic tic disorder, defined as having a tic for more than 1 year (91% vs 86%, χ²₁ = 0.3, P > .10, baseline vs follow-up, respectively). In fact, the average duration of tic disorders was 4.9 ± 3.8 years, representing approximately one third of the lifetime of these children. There was little difference in the average impairment attributed to tic symptoms (mean severity, 1.6 vs 1.2; F_{1,40} = 3.25, P = .08) in sub-

COMORBIDITY AND FUNCTIONAL OUTCOME

No statistically significant differences were detected between subjects with ADHD with and without comorbid tic disorders in any of the multiple outcome measures assessed: psychopathological, cognitive, interpersonal, family, and school functioning (Table). These results were confirmed after reanalyzing the data using the combined sample of probands with ADHD who developed tics at either baseline or follow-up assessments, controlling for age. With the exception of more impaired Global Assessment of Functioning scale scores ($t_{125} = 2.5, P < .02$; $t_{125} = 2.1, P < .04$), higher rates of bipolar disorder ($z = 2.2, P < .03$), and less impaired Moos Family Environment Scale expression scores ($t_{107} = 2.0, P < .05$) in subjects with ADHD and tic disorders vs ADHD alone, respectively, no other meaningful differences were detected.

While 114 (89%) of 128 probands with ADHD were exposed to medication at some point during their lifetime (lifetime exposure), only 56 (44%) of 126 were medicated during the 4-year follow-up period of the study (recent exposure). These recently exposed, medicated subjects were treated with stimulants at a mean methylphenidate-equivalent daily dose of 0.8 ± 0.5 mg/kg. Subjects with ADHD without tic disorders were nonsignificantly more likely to be treated with stimulants compared with subjects with ADHD with tic disorders (40 [48%] of 84 vs 16 [38%] of 42, respectively; $\chi^2_1 = 1.0, P = .3$). Among children who did not have tic disorder at baseline, interval stimulant treatment (recent exposure) was most common in the ADHD group that was youngest (baseline) (25/36 [69%] aged 6-8 years, 14/37 [38%] aged 9-12 years, 10/31 [32%] aged 13 years or older; $\chi^2_2 = 16, P < .001$). However, the rates of new onset of tics were similar (or lower) at each age for subjects with ADHD who were treated with stimulants (tic disorder rates were 32% vs 36% for subjects aged 6-8 years, $\chi^2_1 = 0.1, P = .8$; 7% vs 13% for subjects aged 9-12 years, $\chi^2_1 = 0.3, P = .6$; 0% vs 19% for subjects aged 13 years or older, $\chi^2_1 [2.2] = 0.1, P > .10$; for those treated with stimulants vs those who were not treated, respectively). The rate of onset of tic disorders did not differ by either the presence or absence of lifetime exposure to stimulants (age adjusted, 50% vs 31%; unadjusted, 39 of 114 vs 4 of 14, respectively; $z = 0.39, P > .10$) or recent exposure to stimulants (age adjusted 32% vs 51%; unadjusted, 16 of 56 vs 26 of 70, respectively, $z = 0.54, P > .10$) (Figure 2, left). Only 1 stimulant-treated subject with ADHD with a comorbid tic disorder at baseline progressed to develop TS during the follow-up period. In contrast, although 11 (92%) of the 12 subjects with ADHD with TS at baseline were exposed to stimulants, 9 (75%) had their tic status downgraded to no tics (5 subjects) or to that of a non-TS tic disorder (4 subjects) at follow-up.

COMMENT

In a large, controlled, longitudinal, and naturalistic study of male children and adolescents with ADHD, we found more tic disorders in subjects with ADHD when compared with a control sample of subjects without ADHD. Attention-deficit/hyperactivity disorder and tic disorders had distinct courses, suggesting that the 2 disor-




Figure 1. Top, Age at onset of attention-deficit/hyperactivity disorder (ADHD) and the age at onset of tic disorders in ADHD ($n = 128$). Bottom, Age at remission of ADHD ($n = 128$) and age at remission of tic disorders in ADHD ($n = 43$).

jects with ADHD and tic disorder at baseline and ADHD and tic disorder at follow-up, respectively.

ONSET AND REMISSION OF TIC DISORDERS AND ADHD

The average age at onset of tic disorders in probands with ADHD was significantly later than the average age at onset of ADHD (7.1 ± 4.0 vs 2.6 ± 1.8 years, respectively, $t_{41} = 6.9, P < .001$; Figure 1, left). In all but 3 cases, ADHD preceded the onset of tic disorders. A Cox proportional hazards model showed that the age at onset of ADHD was similar in children with ADHD with and without a lifetime history of tic disorders ($z = 0.43, P > .10$). In contrast to an age-adjusted rate of 20% (unadjusted, 19 of 128) of remission of ADHD, the rate of remission of tic disorders was 65% (unadjusted, 24 of 43) (Figure 1, right). In subjects with both tic disorders and ADHD, their tic disorder was more likely to remit than their ADHD (McNemar $\chi^2_1 = 5.8, P < .02$). The average age at offset of tic disorders of subjects with ADHD was significantly younger than that at offset of ADHD (12.0 ± 3.6 vs 13.3 ± 3.3 years, respectively, $t_{41} = 3.1, P < .01$; Figure 1, right), and offset of tic symptoms was independent of remission of ADHD ($z = 0.83, P > .10$).




Figure 2. Top, Age at onset of tic disorders in probands with attention-deficit/hyperactivity disorder (ADHD) who were exposed or not exposed to stimulants during the 4-year follow-up period of the study ($n = 56$ and $n = 70$, respectively). Bottom, Age at remission of tic disorders in ADHD probands who were exposed or not exposed to stimulants during the 4-year follow-up period of the study ($n = 16$, $n = 26$, respectively).

ders are separate clinical entities. Tic disorders had no adverse effects on the course of ADHD. These findings suggest that comorbidity with a tic disorder has a limited effect on ADHD outcome.

Only 3 prior cross-sectional studies reporting findings in referred ADHD samples evaluated the overlap with tic disorders in children with ADHD, and only 1 of these was controlled.^{6,39,40} Although an early study⁶ reported a low rate (3%) of tic disorders in a survey of clinically referred children with minimal brain disorder, the 2 more recent studies reported higher rates of tics in children with ADHD (50%³⁹ and 32%⁴⁰).

Although failing to reach our threshold for statistical significance, obsessive-compulsive disorder was more common in our patients with ADHD with comorbid tic disorders (18% vs 8% of subjects without tics). Considering the well-documented overrepresentation of obsessive-compulsive disorder in tic disorders,⁴¹⁻⁴³ the comorbidity with obsessive-compulsive disorder in our group of subjects with tics provides further support that they had true tic disorders.

Of the many comparisons, very few suggested that tic disorders contributed to impairment in children with ADHD—the exceptions were more impaired global func-

tioning scores and higher rates of bipolar disorder. Similar associations between mania and TS have been reported in adults.⁴⁴⁻⁴⁶ Considering its severity, the confirmation of an association between tics and mania may lead to refinements in the treatment of complex patients with tics. Families of children with ADHD and tic disorder showed less impairment in our measure of expressiveness than other families with children with ADHD. This finding was unexpected and may be due to chance. Nevertheless, this finding was consistent with our other results in suggesting that the presence of tics was not associated with worse psychosocial function.

Our results suggest that the treatment of ADHD with stimulants has a limited effect on the course of tics. Because this was a naturalistic study, physicians may have chosen not to use stimulants in children with current or past tic disorders. Although our data show that this did not occur, we must be cautious in drawing conclusions about the putative link between tic exacerbation and stimulants. Recent studies, including short-term, placebo-controlled studies with long-term extensions^{22,24} and a controlled discontinuation study,⁴⁷ are beginning to provide more definitive and reassuring data on this issue. However, these studies were not designed to address rates of onset or the course of tic disorders in an ADHD sample unselected for tics. In this regard, our study may be viewed as complementary to these data, providing an indication of the natural course of untreated and treated (or partially treated) tics in an unselected ADHD population.

The findings presented in this report should be evaluated in light of their methodological limitations. The diagnoses of tic disorders and TS were derived from structured diagnostic interviews with the mothers and children aged 12 years or older, not by direct examinations of children. Although this approach may have underestimated the true rate of tics in our study sample, this would not have confounded group comparisons. Moreover, considering the waxing and waning profile of tic disorders and TS, the ability of children to inhibit tics, and the limited ability of children to accurately report a prior history, parental interviews may be quite informative.^{48,49}

Because information on the onset and offset of disorders was retrospective, it may have been vulnerable to recall bias, but should not have confounded group comparisons. As noted, 9 (43%) of 21 of the subjects with ADHD + tic disorder at follow-up reported that the onset of the tic disorder was earlier than their age at baseline. It is likely that mild tics were not reported at the baseline assessment. But, because these worsened over time, they were reported at follow-up and, at that time, their mild manifestations prior to baseline were recalled. Although the average severity of tic disorders in our study was mild to moderate, the average duration of tic disorders was 4 years. In a recent study that investigated the role of tic severity in prevalence bias, 30% of subjects with tic disorders were unaware of tics noted by examiners and only 19% had sought medical care.⁵⁰ The authors concluded that most cases of TS and chronic motor tics were mild and that tic disorders were much more prevalent than generally appreciated.⁵⁰

Owing to sample restrictions, our results cannot be generalized to patients with tic disorders who do not have

ADHD, community samples, females, minorities, or children meeting exclusion criteria.

Because assessments of tic disorders were not independent of that of ADHD at cross-sectional assessments, it is possible that ratings of one disorder were biased by ratings of the other. Such effects are unlikely because: (1) Structured interviews were created to systematize the assessment process in a manner that reduces such biases. Indeed, it is common practice for one rater to assess research participants for several disorders. (2) At the time of assessment we had no a priori hypotheses about the relationship between tic disorders and ADHD.

Despite these limitations, our findings from a large sample of male children and adolescents with ADHD suggest that while tic disorders are overrepresented in ADHD, they have a limited effect on the course of ADHD.

Accepted for publication April 19, 1999.

Preparation of this article was supported in part by a grant from the Tourette Society Association, Bayside, NY (Dr Spencer), and grant K20 MH01169-01 from the National Institute of Mental Health, Bethesda, Md (Dr Spencer).

Reprints: Thomas Spencer, MD, Pediatric Psychopharmacology Unit (ACC-725), Massachusetts General Hospital, Fruit Street, Boston, MA 02114.

REFERENCES

1. Singer HS, Rosenberg LA. Development of behavioral and emotional problems in Tourette syndrome. *Pediatr Neurol*. 1989;5:41-44.
2. Nolan EE, Sverd J, Gadow KD, Sprafkin J, Ezor SN. Associated psychopathology in children with both ADHD and chronic tic disorder. *J Am Acad Child Adolesc Psychiatry*. 1996;35:1622-1630.
3. Stokes A, Bawden HN, Camfield PR, Backman JE, Dooley JM. Peer problems in Tourette's disorder. *Pediatrics*. 1991;87:936-942.
4. Spencer T, Biederman J, Harding M, O'Donnell D, Wilens T, Faraone S, Coffey B, Geller D. Disentangling the overlap between Tourette's disorder and ADHD. *J Child Psychol Psychiatry*. 1998;39:1037-1044.
5. Spencer T, O'Donnell D, Biederman J, Wilens T. Further comparisons of findings between tic disorder and ADHD children: CBCL and social functioning. Paper presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 1996; Philadelphia, Pa.
6. Denckla MB, Bemporad JR, MacKay MC. Tics following methylphenidate administration: a report of 20 cases. *JAMA*. 1976;235:1349-1351.
7. Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. *Arch Pediatr Adolesc Med*. 1994;148:859-861.
8. Law S, Schachar R. Does methylphenidate cause tics? Presented at the Annual Meeting: American Academy of Child and Adolescent Psychiatry; October 1997; Toronto, Ontario.
9. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. *Pediatrics*. 1990;86:184-192.
10. Borcharding BG, Keysor CS, Rapoport JL, Elia J, Amass J. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? *Psychiatry Res*. 1990;33:83-94.
11. Golden GS. The effect of central nervous system stimulants on Tourette syndrome. *Ann Neurol*. 1977;2:69-70.
12. Golden GS. Stimulant medication in Tourette's syndrome. *JAMA*. 1982;248:1063.
13. Shapiro AK, Shapiro E. Do stimulants provoke, cause, or exacerbate tics and Tourette syndrome? *Compr Psychiatry*. 1981;22:265-273.
14. Erenberg G. Stimulant medication in Tourette's syndrome. *JAMA*. 1982;248:1062.
15. Erenberg G, Cruse RP, Rothner AD. Gilles de la Tourette's syndrome: effects of stimulant drugs. *Neurology*. 1985;35:1346-1348.
16. Price RA, Leckman JF, Pauls DL, Cohen DJ, Kidd KK. Gilles de la Tourette's syndrome. *Neurology*. 1986;36:232-237.
17. Comings DE, Comings BG. Tourette's syndrome and attention deficit disorder. In: Cohen DJ, Bruun RD, Leckman JF, eds. *Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment*. New York, NY: John Wiley & Sons Inc; 1988:119-136.
18. Sverd J, Gadow KD, Paolicelli LM. Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette's syndrome. *J Am Acad Child Adolesc Psychiatry*. 1989;28:574-582.
19. Riddle MA, Lynch K, Scahill L, DeVries A, Cohen DJ, Leckman JF. Methylphenidate discontinuation and reinitiation during long-term treatment of children with Tourette's disorder and attention-deficit hyperactivity disorder: a pilot study. *J Child Adolesc Psychopharmacol*. 1995;5:205-214.
20. Gadow KD, Nolan EE, Sverd J. Methylphenidate in hyperactive boys with comorbid tic disorder. II: short-term behavioral effects in school settings. *J Am Acad Child Adolesc Psychiatry*. 1992;31:462-471.
21. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder [published correction appears in *Arch Gen Psychiatry*. 1995;52:836]. *Arch Gen Psychiatry*. 1995;52:444-455.
22. Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, Rapoport JL. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. *J Am Acad Child Adolesc Psychiatry*. 1997;36:589-596.
23. Konkol R, Fischer M, Newby R. Double-blind, placebo-controlled stimulant trial in children with Tourette's syndrome and ADHD [abstract]. *Ann Neurol*. 1990;28:424.
24. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long-term methylphenidate therapy in children with comorbid ADHD and chronic multiple tic disorder. *Arch Gen Psychiatry*. In press.
25. Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, Mennin D, Marrs A, Ouellette C, Moore P, Spencer T, Norman D, Wilens T, Kraus I, Perrin J. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. *Arch Gen Psychiatry*. 1996;53:437-446.
26. Biederman J, Faraone SV, Keenan K, Benjamin J, Krifcher B, Moore C, Sprich-Buckminster S, Uraglia K, Jellinek MS, Steingard R, Spencer T, Norman D, Kolodny R, Kraus I, Perrin J, Keller MB, Tsuang MT. Further evidence for family-genetic risk factors in attention-deficit hyperactivity disorder (ADHD). *Arch Gen Psychiatry*. 1992;49:728-738.
27. Orvaschel H. Psychiatric interviews suitable for use in research with children and adolescents. *Psychopharmacol Bull*. 1985;21:737-745.
28. Sattler JM. *Assessment of Children*. San Diego, Calif: J. M. Sattler; 1988.
29. Jastak JF, Jastak S. *The Wide Range Achievement Test-Revised*. Wilmington, Del: Jastak Associates; 1985.
30. Assistance to states for education for handicapped children: procedures for evaluating specific learning disabilities, 42. *Federal Register* (1977).
31. Reynolds CR. Critical measurement issues in learning disabilities. *J Special Educ*. 1984;18:451-476.
32. Spitzer RL, Williams JB, Gibbon M, First MB. *Structured Clinical Interview for DSM-III-R: Non-Patient Edition (SCID-NP, Version 1.0)*. Washington, DC: American Psychiatric Press; 1990.
33. Hollingshead AB. *Four Factor Index of Social Status*. New Haven, Conn: Yale University, Department of Sociology; 1975.
34. Achenbach TM. *Manual for the Child Behavior Checklist/4-18 and 1991 Profile*. Burlington: University of Vermont Department of Psychiatry; 1991.
35. Orvaschel H, Walsh G. *Assessment of Adaptive Functioning in Children: A Review of Existing Measures Suitable for Epidemiological and Clinical Services Research*. Washington, DC: US Dept of Health and Human Services, National Institute of Mental Health, Division of Biometry and Epidemiology; 1984.
36. Biederman J, Faraone S, Chen W. Social adjustment inventory for children and adolescents: concurrent validity in ADHD children. *J Am Acad Child Adolesc Psychiatry*. 1993;32:1059-1064.
37. Moos RH, Moos BS. *Family Environment Scale: Manual*. Palo Alto, Calif: Consulting Psychologists Press Inc; 1981.
38. Stata Corporation. *Stata Reference Manual: Release 5*. College Station, Tex: Stata Corporation; 1997.
39. Comings DE, Comings BG. A controlled family history study of Tourette's syndrome. I: attention-deficit hyperactivity disorder and learning disorders. *J Clin Psychiatry*. 1990;51:275-280.
40. Munir K, Biederman J, Kneel D. Psychiatric comorbidity in patients with attention deficit disorder. *J Am Acad Child Adolesc Psychiatry*. 1987;26:844-848.
41. Comings DE, Comings BG. A controlled study of Tourette syndrome, IV: obsessions, compulsions, and schizoid behaviors. *Am J Hum Genet*. 1987;41:782-803.
42. Pauls DL. The genetics of obsessive-compulsive disorder and Gilles de la Tourette's syndrome. *Psychiatr Clin North Am*. 1992;15:759-766.
43. Pauls DL, Alsobrook JP 2nd, Goodman W, Rasmussen S, Leckman JF. A family study of obsessive-compulsive disorder. *Am J Psychiatry*. 1995;152:76-84.
44. Kerbeshian J, Burd L, Klug MG. Comorbid Tourette's disorder and bipolar disorder: an etiologic perspective. *Am J Psychiatry*. 1995;152:1646-1651.
45. Comings BG, Comings DE. A controlled study of Tourette syndrome, V: depression and mania. *Am J Hum Genet*. 1987;41:804-8021.
46. Berthier ML, Kulisevsky J, Campos VM. Bipolar disorder in adult patients with Tourette's syndrome: a clinical study. *Biol Psychiatry*. 1998;43:364-370.
47. Nolan EE, Gadow KD, Sprafkin J. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. *Pediatrics*. 1999;103:730-737.
48. Schwab-Stone M, Fallon T, Briggs M, Crowther B. Reliability of diagnostic reporting for children aged 6-11 years. *Am J Psychiatry*. 1994;151:1048-1054.
49. Leckman JF, Walker DE, Cohen DJ. Premonitory urges in Tourette's syndrome. *Am J Psychiatry*. 1993;150:98-102.
50. Kurlan R, Behr J, Medved L, Shoulson I, Pauls D, Kidd KK. Severity of Tourette's syndrome in one large kindred. *Arch Neurol*. 1987;44:268-269.